Longboard Pharmaceuticals
Clinical-stage biopharmaceutical company focused on developing small-molecule, centrally acting medicines for neurological and rare diseases. Built from a GPCR discovery platform, the company advanced multiple GPCR-targeted candidates through preclinical and early clinical development and engaged in partnerships and community outreach. Longboard became a wholly owned subsidiary of Lundbeck following a completed acquisition on December 2, 2024.
Industries
Nr. of Employees
medium (51-250)
Longboard Pharmaceuticals
San Diego, California, United States
Products
Bexicaserin (5-HT2C receptor superagonist candidate, LP352)
Oral, centrally acting small-molecule candidate designed as a selective 5-HT2C receptor superagonist for potential treatment of developmental and epileptic encephalopathies and refractory epilepsies.
S1P receptor modulator candidate (LP659)
Oral, centrally acting small-molecule candidate modulating sphingosine-1-phosphate receptor subtypes 1 and 5 in development for CNS neuroinflammatory diseases; entered first-in-human Phase 1 studies.
CB2 receptor full agonist candidate (LP143)
Oral, centrally acting cannabinoid type 2 (CB2) receptor full agonist candidate developed for potential treatment of CNS diseases associated with neuroinflammation; completed IND-enabling studies and undergoing additional preclinical work.
Bexicaserin
Bexicaserin (LP352) is an investigational oral 5-HT2C superagonist designed to be highly selective and target developmental and epileptic encephalopathies (DEEs) and other refractory epilepsies.
Bexicaserin (LP352)
An oral, centrally acting, 5-HT2C superagonist in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies (DEEs).
Bexicaserin (5-HT2C receptor superagonist candidate, LP352)
Oral, centrally acting small-molecule candidate designed as a selective 5-HT2C receptor superagonist for potential treatment of developmental and epileptic encephalopathies and refractory epilepsies.
S1P receptor modulator candidate (LP659)
Oral, centrally acting small-molecule candidate modulating sphingosine-1-phosphate receptor subtypes 1 and 5 in development for CNS neuroinflammatory diseases; entered first-in-human Phase 1 studies.
CB2 receptor full agonist candidate (LP143)
Oral, centrally acting cannabinoid type 2 (CB2) receptor full agonist candidate developed for potential treatment of CNS diseases associated with neuroinflammation; completed IND-enabling studies and undergoing additional preclinical work.
Bexicaserin
Bexicaserin (LP352) is an investigational oral 5-HT2C superagonist designed to be highly selective and target developmental and epileptic encephalopathies (DEEs) and other refractory epilepsies.
Bexicaserin (LP352)
An oral, centrally acting, 5-HT2C superagonist in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies (DEEs).
Expertise Areas
- Clinical trial management
- Clinical pharmacology and PK/PD
- GPCR-targeted small-molecule drug discovery
- Preclinical seizure models and translational science
Key Technologies
- GPCR-focused small-molecule discovery
- In vivo seizure models (including zebrafish scn1lab)
- Plasma and CSF pharmacokinetic assays
- EEG/QEEG biomarker assessments
News & Updates
H. Lundbeck A/S completed the acquisition of Longboard Pharmaceuticals, making Longboard a wholly owned subsidiary of Lundbeck.
Announcement of the initiation of first-in-human Phase 1 clinical study for the S1P receptor modulator candidate in adult healthy volunteers.
Presentation of single-ascending-dose and multiple-ascending-dose Phase 1 pharmacokinetics, pharmacodynamics, and tolerability data at the American Academy of Neurology Annual Meeting.
Initiated PACIFIC Study to evaluate the 5-HT2C superagonist candidate in participants with developmental and epileptic encephalopathies.
Abstracts and posters reporting PK/PD, CSF exposure, QEEG biomarker findings, drug-drug interaction potential, and preclinical efficacy were presented at AES, AAN, IEC, ACCP and EEC meetings.
Reported statistically significant reductions in epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndrome.
H. Lundbeck A/S completed the acquisition of Longboard Pharmaceuticals, making Longboard a wholly owned subsidiary of Lundbeck.
Announcement of the initiation of first-in-human Phase 1 clinical study for the S1P receptor modulator candidate in adult healthy volunteers.
Presentation of single-ascending-dose and multiple-ascending-dose Phase 1 pharmacokinetics, pharmacodynamics, and tolerability data at the American Academy of Neurology Annual Meeting.
Initiated PACIFIC Study to evaluate the 5-HT2C superagonist candidate in participants with developmental and epileptic encephalopathies.
Abstracts and posters reporting PK/PD, CSF exposure, QEEG biomarker findings, drug-drug interaction potential, and preclinical efficacy were presented at AES, AAN, IEC, ACCP and EEC meetings.
Reported statistically significant reductions in epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndrome.